reports
Update: A late-stage company in early-stage clothing
Thanks to the license agreement with Brighthaven Ventures (“BHVâ€), Islet has catapulted to late-stage status, with two Phase IIb programmes for major indications (type II diabetes and NASH). Importantly, remogliflozin etabonate (remo) has the potential to be a best-in-class SGLT2 inhibitor.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.